Efficacy and Safety of Semaglutide for Weight Loss in Overweight or Obese Adults in Bangladesh With or Without Type 2 Diabetes Mellitus

A phase 3 trial registered on ClinicalTrials.gov. The registry status is unknown. It plans to enroll 480 participants.

Also called NCT06616961

  • Study
  • In this atlas

Overview

Design
Interventional study; allocation not applicable; no masking; primary purpose treatment
Phase
Phase 3
Enrolled
  • 480 participants (planned count) (from the registry)
Sponsor
Popular Medical College Hospital (from the registry)
Registry
  • NCT NCT06616961
Planned start
(anticipated) (from the registry)
Primary completion
(anticipated) (from the registry)
Completion
(anticipated) (from the registry)
Countries
Bangladesh (from the registry)
Registry status
  • Unknown status (from the registry)

Technical summary

Registry record NCT06616961. Allocation not applicable; no masking; primary purpose treatment. Start 2024-11-01 (anticipated); primary completion 2025-02 (anticipated). Results not posted.

The registry's words

Labels as the registry gives them, not rewritten.

Brief title
Efficacy and Safety of Semaglutide for Weight Loss in Overweight or Obese Adults in Bangladesh With or Without Type 2 Diabetes Mellitus
Condition
Obesity
Condition
Type 2 Diabetes Mellitus (T2DM)
Intervention (Drug)
Semaglutide Pen
Lead sponsor
Popular Medical College Hospital (class: other)
Collaborator
Pi Research and Development Center, Bangladesh (class: not stated)
Collaborator
Incepta Pharmaceuticals Ltd (class: industry)

Record details

Record id
cardio:ct-nct06616961
Content hash
e59bcadce6027d73d2aed89f535916bd3f4042059695656107794562b519e83b